What OncoMed Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Pakianathan Deepika | Director | Apr 23 | Tender Offer · U | −18,940 | — | — | 0 |
| Pakianathan Deepika | Director | Apr 23 | Tender Offer · U | −1,991,602 | — | — | 0 |
| Root Jonathan D | Director | Apr 23 | Tender Offer · U | −121,020 | — | — | 0 |
| Stagg Robert | See Remarks | Apr 23 | Tender Offer · U | −28,917 | — | — | 0 |
| Lewicki John A. | President and CEO | Apr 23 | Tender Offer · U | −142,534 | — | — | 0 |
| Li Yvonne | See Remarks | Apr 23 | Tender Offer · U | −65,895 | — | — | 0 |
| Hager Alicia J. | SVP and General Counsel | Apr 23 | Tender Offer · U | −39,488 | — | — | 0 |
| Lasersohn Jack W | Director | Apr 23 | Tender Offer · U | −380,299 | — | — | 0 |
| Lasersohn Jack W | Director | Apr 23 | Tender Offer · U | −1,119,905 | — | — | 0 |
| Lasersohn Jack W | Director | Apr 23 | Tender Offer · U | −185,709 | — | — | 0 |
| Karsen Perry A | Director | Apr 23 | Tender Offer · U | −80,500 | — | — | 0 |
| Gurney Austin | See Remarks | Dec 24 | Open-market sale · S | −11,117 | $0.60 | −$6.67K | 66,807 |
| Hager Alicia J. | SVP & General Counsel | Oct 10 | Open-market sale · S | −1,156 | $2.02 | −$2.34K | 51,754 |
| Lewicki John A. | President & CEO | Oct 10 | Open-market sale · S | −1,156 | $2.01 | −$2.32K | 55,966 |
| Li Yvonne | See Remarks | Oct 10 | Open-market sale · S | −927 | $2.02 | −$1.87K | 59,734 |
| Stagg Robert | SVP, Clinical R&D | Oct 10 | Open-market sale · S | −927 | $2.01 | −$1.86K | 40,670 |
| Gurney Austin | See Remarks | Oct 10 | Open-market sale · S | −1,156 | $2.01 | −$2.32K | 77,924 |
| Hager Alicia J. | SVP & General Counsel | Oct 09 | Open-market sale · S | −1,686 | $2.13 | −$3.59K | 52,910 |
| Lewicki John A. | President & CEO | Oct 09 | Open-market sale · S | −2,296 | $2.13 | −$4.89K | 57,122 |
| Li Yvonne | See Remarks | Oct 09 | Open-market sale · S | −1,229 | $2.13 | −$2.62K | 60,661 |
Loading...
